Evercore ISI reissued their outperform rating on shares of Rallybio (NASDAQ:RLYB – Free Report) in a research note released on Monday, Benzinga reports. The brokerage currently has a $15.00 price target on the stock.
A number of other equities analysts have also commented on the stock. HC Wainwright decreased their price objective on shares of Rallybio from $9.00 to $6.00 and set a buy rating for the company in a research note on Monday, August 12th. JPMorgan Chase & Co. cut Rallybio from an overweight rating to a neutral rating in a research report on Wednesday, May 15th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of Moderate Buy and an average price target of $10.00.
Get Our Latest Analysis on Rallybio
Rallybio Stock Down 6.5 %
Rallybio (NASDAQ:RLYB – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.05. The company had revenue of $0.30 million for the quarter. As a group, analysts anticipate that Rallybio will post -1.45 earnings per share for the current year.
Institutional Investors Weigh In On Rallybio
A number of institutional investors have recently modified their holdings of the stock. Almitas Capital LLC acquired a new position in shares of Rallybio in the second quarter worth $135,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Rallybio in the 2nd quarter worth about $61,000. Hsbc Holdings PLC purchased a new stake in shares of Rallybio during the 2nd quarter worth about $25,000. Johnson & Johnson purchased a new stake in shares of Rallybio during the 2nd quarter worth about $4,873,000. Finally, Acadian Asset Management LLC lifted its holdings in shares of Rallybio by 116.3% during the 2nd quarter. Acadian Asset Management LLC now owns 67,695 shares of the company’s stock valued at $89,000 after buying an additional 36,401 shares during the last quarter. Institutional investors and hedge funds own 90.34% of the company’s stock.
Rallybio Company Profile
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.
Featured Stories
- Five stocks we like better than Rallybio
- Want to Profit on the Downtrend? Downtrends, Explained.
- BHP Stock: The Under-the-Radar Growth Story in Commodities
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Analysts Upgrade These 3 Hot Buy-and-Hold Stocks
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Kohl’s Charts a Resilient Path in a Challenging Retail Landscape
Receive News & Ratings for Rallybio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rallybio and related companies with MarketBeat.com's FREE daily email newsletter.